Toripalimab

Generic Name: Toripalimab

Brand Names: Loqtorzi

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1924598-82-2

Unique Ingredient Identifier: 8JXN261VVA

Background: Toripalimab is under investigation in clinical trial NCT03919383 (Phase II of Lenvatinib Plus Toripalimab for Advanced HCC).

Indication: ⑴用于治疗既往标准治疗失败后的局部进展或转移性黑色素瘤。⑵用于治疗既往接受过二线及以上系统治疗失败的复发/转移性鼻咽癌（NPC）。⑶用于治疗既往接受过治疗的局部进展或转移性尿路上皮癌（UC）。⑷用于食管鳞癌一线治疗。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

The Optimal Radioimmunotherapy Combinations for Advanced TNBC

Phase 2

Not yet recruiting

Conditions: Triple-Negative Breast Cancer (TNBC)

Interventions: Radiation: radiotehrapy 0.5Gy twice-a-day × 2 days, repeat for 4 cycles (total 8Gy)
Radiation: radiotherapy 5 Gy × 5 fractions, once a day
Radiation: radiotherapy 8 Gy × 5 fractions, once a day
Radiation: radiotherapy 8 Gy × 3 fractions, once every other day
Radiation: radiotherapy 10 Gy× 3 fractions, once every other day
Drug: Toripalimab
Drug: chemotherapy regimen selected by the investigator

First Posted Date: 2024-12-16

Last Posted Date: 2024-12-16

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 60

Registration Number: NCT06735131

Low-dose Radiotherapy Combined with Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC

Phase 1

Not yet recruiting

Conditions: Extensive-stage Small-cell Lung Cancer

Interventions: Radiation: Low-dose radiotherapy
Drug: Tifcemalimab injection
Drug: Toripalimab
Drug: Cisplatin
Drug: Carboplatin
Drug: Etoposide

First Posted Date: 2024-12-13

Last Posted Date: 2024-12-13

Lead Sponsor: Sichuan University

Target Recruit Count: 12

Registration Number: NCT06732258

Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer

Phase 2

Active, not recruiting

Conditions: Gallbladder Cancer
Hilar Cholangiocarcinoma
Distal Cholangiocarcinoma

Interventions: Drug: Capecitabine
Drug: Toripalimab

First Posted Date: 2024-12-05

Last Posted Date: 2024-12-05

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 110

Registration Number: NCT06717464

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS

First Posted Date: 2024-11-18

Last Posted Date: 2024-11-18

Lead Sponsor: Peking University Shenzhen Hospital

Target Recruit Count: 200

Registration Number: NCT06692491

Combination of Toripalimab and JS004 Therapy for ccRCC

Phase 2

Recruiting

Conditions: Clear Cell Renal Cell Carcinoma

Interventions: Drug: Axitinib
Drug: JS004
Drug: Sorafenib
Drug: Toripalimab

First Posted Date: 2024-11-15

Last Posted Date: 2024-11-15

Lead Sponsor: Fudan University

Target Recruit Count: 80

Registration Number: NCT06690697

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma

Phase 2

Not yet recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Casdozokitug
Drug: Toripalimab
Drug: Bevacizumab

First Posted Date: 2024-11-08

Last Posted Date: 2024-11-08

Lead Sponsor: Coherus Biosciences, Inc.

Target Recruit Count: 72

Registration Number: NCT06679985

A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

Phase 1

Not yet recruiting

Conditions: Metastatic Solid Tumor
Advanced Solid Tumor

Interventions: Drug: CHS-114
Drug: Toripalimab

First Posted Date: 2024-10-24

Last Posted Date: 2024-10-24

Lead Sponsor: Coherus Biosciences, Inc.

Target Recruit Count: 40

Registration Number: NCT06657144

Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)

Phase 3

Not yet recruiting

Conditions: Squamous Cell Carcinoma of Head and Neck

Interventions: Biological: Toripalimab
Biological: Cetuximab
Drug: Albumin-Bound Paclitaxel
Drug: Carboplatin
Drug: Cisplatin
Radiation: Radiotherapy 60 Gray/day
Radiation: Radiotherapy 66 Gray/day
Radiation: Radiotherapy 70 Gray/day

First Posted Date: 2024-10-18

Last Posted Date: 2024-10-18

Lead Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Target Recruit Count: 355

Registration Number: NCT06647563

Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer

Phase 2

Not yet recruiting

Conditions: Small Cell Lung Cancer Extensive Stage
Small Cell Lung Cancer Recurrent

Interventions: Drug: Toripalimab
Drug: JS004
Drug: Etoposide
Drug: Platinum

First Posted Date: 2024-10-18

Last Posted Date: 2024-10-18

Lead Sponsor: Shanghai Pulmonary Hospital, Shanghai, China

Target Recruit Count: 100

Registration Number: NCT06648200

Locations: 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China

Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer

Phase 2

Not yet recruiting

Conditions: Breast Cancer

Interventions: Drug: Disitamab Vedotin
Drug: Albumin-bound Paclitaxone
Drug: RC148
Drug: Toripalimab

First Posted Date: 2024-10-15

Last Posted Date: 2024-10-24

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 40

Registration Number: NCT06642545

Locations: 🇨🇳
Cance Hosoltal Chinese Academy of Medical Sciences, Beijing, Beijing, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy